Christchurch mutation points to potential gene therapy avenue for Parkinson's

by Erik Robinson, Oregon Health & Science University

edited by Robert Egan

Robert Egan

Senior Editor

Meet our editorial team
Behind our editorial process
Editors' notes

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

peer-reviewed publication

trusted source

proofread

The GIST Add to Preferred Sources

A rare genetic mutation may protect against developing Parkinson's disease and Lewy body dementia, a new study from researchers at Oregon Health & Science University suggests.

The study, published in the journal Cell Reports, for the first time suggests a link to Parkinson's involving the so-called Christchurch mutation of the APOE gene. The study raises the possibility of gene therapy approaches to forestall cognitive and motor impairments in Parkinson's and related conditions.

Previous research—starting with the 2019 case of a woman from Colombia who carried the rare mutation first discovered in New Zealand—found that the mutation seems to forestall symptoms of dementia in people who are otherwise genetically destined to develop Alzheimer's disease.

OHSU researchers working in a rodent model have now discovered a link to Parkinson's.

"It opens up this idea that this Christchurch mutation could be helpful for a lot of things we didn't realize before," said senior author Vivek Unni, M.D., Ph.D., associate professor of neurology in the OHSU School of Medicine.

Protection against two damaging proteins

Other studies in animal models have shown the Christchurch mutation prevents the aggregation of the Alzheimer's-related tau protein in the brain.

The OHSU study published confirms the same process in tau, while also going a step further and showing that the Christchurch mutation prevents the accumulation of a different type of protein, known as alpha-synuclein, that typifies the progression of Parkinson's and Lewy body dementia.

OHSU scientists used mouse models that are predisposed to accumulate alpha-synuclein and tau proteins in the brain.

Then, they added the Christchurch mutation to the APOE gene to see what would happen.

In each case, mice with the Christchurch mutation did not accumulate tau or alpha-synuclein proteins in the brain, despite their predisposition. In effect, the mutation seemed to protect the brain from the accumulation of proteins believed to drive both Alzheimer's and Parkinson's diseases.

Toward Christchurch gene therapy

Already, gene therapies are being developed to leverage another, more common version of the APOE gene (APOE-2) that also seems to be protective against Alzheimer's.

Unni said the Christchurch mutation seems to be even more protective than APOE-2 and "acts like a super-APOE-2," at least in the mouse model examined in the new study. His lab hopes to extend its preclinical research, with an eye toward eventually moving it far enough to convince drug companies to invest in APOE Christchurch gene therapy clinical trials with people. "It would take several years to test the idea," he said.

Publication details

Carlos M. Soto-Faguás et al., Mouse APOE Christchurch protects against Aβ-induced tau and α-synuclein aggregation, Cell Reports (2026). DOI: 10.1016/j.celrep.2026.118301

Journal information: Cell Reports

Key medical concepts

Parkinson's Diseasealpha-Synucleintau ProteinsDementia with Lewy bodies

Clinical categories

NeurologyClinical genetics Provided by Oregon Health & Science University Who's behind this story?

Robert Egan

Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →

Citation: Christchurch mutation points to potential gene therapy avenue for Parkinson's (2026, November 11) retrieved 11 November 2026 from https://medicalxpress.com/news/2026-11-christchurch-mutation-potential-gene-therapy.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.